Permeability of the blood-brain barrier to the neurotensin8-13 analog NT1.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Brain Research

• Publication date

  1995-10-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0006-8993(95)00836-FPMID 8574648
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure-activity and conformational studies of a series of modified C-terminal hexapeptide neurotensin analogues.

  2009cited by this paper
• Agonist properties of a stable hexapeptide analog of neurotensin, N alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1).

  1995cited by this paper
• Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists.

  1995cited by this paper
• Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine.

  1994cited by this paper
• Acute administration of neuroleptics decreases neurotensin metabolism on intact, regional rat brain slices.

  1994cited by this paper
• Murine tumor necrosis factor alpha is transported from blood to brain in the mouse.

  1993cited by this paper
• Pharmacokinetics of novel hexapeptides with neurotensin activity in rats.

  1993cited by this paper
• Chronic ethanol administration downregulates neurotensin receptors in long- and short-sleep mice.

  1993cited by this paper
• Expression of the Proneurotensin Gene in the Rat Brain and Its Regulation by Antipsychotic Drugs a

  1992cited by this paper
• Physiological Mechanisms of the Analgesic Effect of Neurotensin

  1992cited by this paper
• Peptides and the Blood-Brain Barrier

  1992cited by this paper
• Delivering Peptides to the Central Nervous System: Dilemmas and Strategies

  1991cited by this paper
• Spinal transection reduces both spinal antinociception and CNS concentration of systemically administered morphine in rats.

  1991cited by this paper
• Some characteristics of specific angiotensin II binding sites on bovine brain microvessel endothelial cell monolayers.

  1991cited by this paper
• Stability of a novel hexapeptide, (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt, with neurotensin activity, in aqueous solution and in the solid state.

  1990cited by this paper
• High-performance liquid chromatographic determination of (Me)Arg-Lys-Pro-Trp-tert.-Leu-Leu in plasma.

  1990cited by this paper
• Angiotensin Peptide Regulation of Fluid-Phase Endocytosis in Brain Microvessel Endothelial Cell Monolayers

  1990cited by this paper
• Peptide transport systems for opiates across the blood-brain barrier.

  1990cited by this paper
• Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins

  1990cited by this paper
• Pharmacokinetics and metabolism of neurotensin in man.

  1989cited by this paper
• Reduced CSF neurotensin concentration in drug-free schizophrenic patients.

  1988cited by this paper
• Age-related decreases in the concentration of Met- and Leu-enkephalin and neurotensin in the basal ganglia of rats.

  1987cited by this paper
• Changes in Regional Blood–Brain Transfer of l‐Leucine Elicited by Arginine‐Vasopressin

  1986cited by this paper
• Solid Phase Peptide Synthesis

  1984cited by this paper
• Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data

  1983cited by this paper
• CSF-plasma relationships for DSIP and some other neuropeptides.

  1983cited by this paper
• Transport of α-Aminoisobutyric Acid across Brain Capillary and Cellular Membranes

  1983cited by this paper
• Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes.

  1983cited by this paper
• Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.

  1983cited by this paper
• The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami.

  1973cited by this paper

• Novel single-domain antibodies targeting a unique transferrin receptor 1 epitope for cross-species delivery of drugs in the central nervous system.

  2025cites this paper
• A peptide-neurotensin conjugate that crosses the blood-brain barrier induces pharmacological hypothermia associated with anticonvulsant, neuroprotective, and anti-inflammatory properties following status epilepticus in mice

  2024cites this paper
• Neurotensin agonist PD 149163 modulates the neuroinflammation induced by bacterial endotoxin lipopolysaccharide in mice model

  2022cites this paper
• The Emerging Role of Neuropeptides in Parkinson’s Disease

  2021cites this paper
• The Gut–Brain Axis and Peroxisome Proliferator-Activated Receptors in the Regulation of Epileptogenesis

  2021cites this paper
• Protective effect of neurotensin receptor-1 agonist PD 149163 against lipopolysaccharide-induced gut toxicity in mice

  2021cites this paper
• Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy

  2020cites this paper
• Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

  2015cites this paper
• Diverse Roles of Neurotensin Agonists in the Central Nervous System

  2013influential citation
• Cardio-respiratory effects of systemic neurotensin injection are mediated through activation of neurotensin NTS₁ receptors.

  2012cites this paper
• Pulmonary , gastrointestinal and urogenital pharmacology Cardiorespiratory effects of systemic neurotensin injection are mediated through activation of neurotensin NTS 1 receptors

  2012cites this paper
• Anticonvulsant neuropeptides as drug leads for neurological diseases.

  2011cites this paper
• Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues.

  2009cites this paper
• Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy.

  2009cites this paper
• The Brattleboro Rat Displays a Natural Deficit in Social Discrimination that is Restored by Clozapine and a Neurotensin Analogue

  2009cites this paper
• Emerging evidence for neurotensin receptor 1 antagonists as novel pharmaceutics in neurodegenerative disorders.

  2009cites this paper
• Bioactive analogs of neurotensin: focus on CNS effects.

  2006cites this paper
• In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues.

  2003cites this paper
• The antioxidants α‐lipoic acid and N‐acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice

  2003influential citation
• Clinically validated peptides as templates for de novo peptidomimetic drug design at G-protein-coupled receptors.

  2003cites this paper
• Transport of an Antifungal Trypsin Inhibitor Isolated from Corn across the Blood-Brain Barrier

  2002cites this paper
• The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin.

  2002cites this paper
• Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes.

  2002cites this paper
• Neurotensin analog NT69L induces rapid and prolonged hypothermia after hypoxic ischemia.

  2001cites this paper
• Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist.

  1999cites this paper
• Drug disposition and targeting. Transport across the blood-brain barrier.

  1999cites this paper
• In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier.

  1999cites this paper
• Synthesis and human neurotensin receptor binding activities of neurotensin(8-13) analogues containing position 8 alpha-azido-N-alkylated derivatives of ornithine, lysine, and homolysine.

  1999cites this paper
• Bioavailability and transport of peptides and peptide drugs into the brain.

  1997cites this paper
• A C-terminal cyclic 8-13 neurotensin fragment analog appears less exposed to neprilysin when it crosses the blood-brain barrier than the cerebrospinal fluid-brain barrier in mice.

  1996cites this paper
• Passage of peptides across the blood-brain barrier: pathophysiological perspectives.

  1996cites this paper